Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Follow-Up Questions
Quel est le ratio P/E de Puma Biotechnology Inc (PBYI) ?
Le ratio P/E de Puma Biotechnology Inc est de 7.4031
Qui est le CEO de Puma Biotechnology Inc ?
Mr. Alan Auerbach est le Chairman of the Board de Puma Biotechnology Inc, il a rejoint l'entreprise depuis 2010.
Quelle est la performance du prix de l'action PBYI ?
Le prix actuel de PBYI est de $5.47, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Puma Biotechnology Inc ?
Puma Biotechnology Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Puma Biotechnology Inc ?
La capitalisation boursière actuelle de Puma Biotechnology Inc est de $275.5M
Est-ce que Puma Biotechnology Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Puma Biotechnology Inc, y compris 0 achat fort, 1 achat, 3 maintien, 2 vente et 0 vente forte
